Cellenkos Presents Phase 1b Data at ASH 2024 Showcasing the Potential of T-Regulatory Cell Therapy Candidate CK0804 for Myelofibrosis - Safety profile established and encouraging efficacy signals demonstrated by reductions in spleen volume and symptom burden scores - Data underscore the vast potential of allogeneic, non-HLA...